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Abstract In the normal rodent breast, the pineal hormone
melatonin controls the development of ductal and alveolar
tissue. Melatonin counteracts tumor occurrence and tumor
cell progression in vivo and in vitro in animal and human
breast cancer cell cultures. It acts predominantly through
its melatonin MT1 receptor. Our aim was to investigate the
presence or absence of the MT1 melatonin receptor in the
aggressive triple negative group of human breast carci-
noma (TNBC) and its possible relationship to the course of
the disease. A total of 167 patients with a ER-, PR-, Her-
2/neu- phenotype in which tissue for receptor studies was
available were examined. The MT1 receptor immunostain
was evaluated semiquantitatively as staining intensity (0, 1,
2, 3), percentage of stained cells and the weighted index
(WI) (staining intensity times percentage of stained cells).
A score of WI \ 60 was regarded as ‘‘negative’’. There
was a striking difference in incidence of MT1 positivity
and staining intensity between carcinomas in African
American (AA) and Caucasian (C) women. The AA
showed a higher incidence of MT1 negative tumors (41/
84 = 48.8 % in AA, 6/51 = 11.8 % in C) and a lower
average WI. MT1 positivity in TNBC was associated with
a lower stage and a smaller tumor size at time of diagnosis.
In multivariable survival analysis, MT1 negative TNBC in
all cases regardless of race showed a significantly higher
hazard ratio for disease progression, shorter progression
free survival, and disease-related death, and shorter OS.
This was especially pronounced in the AA group but did
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not reach statistical significance in the smaller group of C
alone. These results suggest that melatonin or a melatonin
receptor agonist may be useful biologic additions in the
treatment of some forms of TNBC, especially in AA who
generally show a more aggressive course of their disease.
Keywords Melatonin receptor MT1  Triple negative
breast cancer  Racial disparity  African American 
Breast cancer
Introduction
Melatonin is the main secretory product of the pineal
gland. It is secreted in a high amplitude circadian periodic
pattern, the timing of which is determined by the envi-
ronmental light–dark regimen [1, 2]. Melatonin acts both
through non-receptor-dependent anti-oxidative and recep-
tor-dependent mechanisms. Two types of G-protein-bound
specific high affinity receptors (MT1 and MT2) are
described [3–5].
In addition to effects upon the endocrine and immune
systems, melatonin exerts, via the MT1 receptor, direct
regulatory actions on cell proliferation [4]. In the normal
rodent breast, melatonin controls the development of ductal
and alveolar tissue [6], and counteracts tumor occurrence
and tumor cell proliferation in vivo and in vitro (e.g., Hill
et al. [6]; Blask et al. [7]). Anti-proliferative actions of
melatonin on human and animal tumor cell lines and in
animal models have been reported for breast cancer [6, 8–
10], prostate cancer [11, 12], colon cancer [13], some but
not all ovarian cancers [14], endometrial cancer [15], liver
cancer (hepatoma 7288 CTC) [16], pancreatic cancer [17],
malignant melanoma [18–20], oral squamous cell carci-
noma [21], and glioma cells [22].
The oncostatic and anti-invasive actions of melatonin
and of melatonin receptor agonists [23] are mediated via
the MT1 melatonin receptor [6], are enhanced by MT1
receptor overexpression [6, 24], and are inhibited by lu-
zindole, a MT1 inhibitor [6]. In physiologic concentration,
melatonin suppresses the growth of both estrogen receptor
alpha (ERa)-positive (MCF-7, T47D, ZR 75-1) and some
ERa-negative (MDA-MB-468) human breast cancer cell
lines in vitro. The proliferation of other ERa-negative cell
lines (MDA-MB-231, MDA-MB-336, and BT-20) is not
inhibited by melatonin [6, 8, 25].
In some studies, the expression of the MT1 receptor
correlated positively with the expression of the ERa
receptor [26]. By way of activating its MT1 receptor, mel-
atonin can suppress the development of cancer via a broad
spectrum of mechanisms with and without involvement of
ERa [6]. In rodents, melatonin in vivo inhibits the devel-
opment and growth of both carcinogen-induced [27, 28] and
spontaneously developing [29, 30] mammary tumors acting
through melatonin receptor-mediated mechanisms [31, 32].
The development of specific antibodies [33] allowed the
study of MT1 receptors in histologic sections of human
breast and breast carcinomas [26, 34]. With immunohis-
tochemistry, MT1 cytoplasmic activity is expressed in
benign luminal breast epithelial cells. The receptor was
absent or weak in ducts and acini in 68 % of cases. In
contrast, moderate to strong reactivity was seen in most
(75 %) of the cases of ductal carcinoma in situ (DCIS) and
invasive ductal carcinoma (IDC). In the available studies,
no mention was made of the triple negative phenotype of
breast cancer.
The triple negative variant of human breast cancer
(TNBC) (ER-, PR-, HER2/neu-) includes several dif-
ferent molecular patterns and different phenotypes with
varying expression of basal and luminal markers [35–37],
and differences in course and outcome [37, 38]. There are
differences between ethnic groups with a higher incidence
and more aggressive course in AA women [39] and in
Hispanic women [40]. The MT1 receptor status in TNBC is
at this time unknown. The use of melatonin as supportive
treatment of breast cancer has been suggested on the basis
of preclinical data [7, 9, 41] and several small clinical trials
[42–46], none including the triple negative phenotype.
There is presently no targeted biologic treatment for these
tumors as is available for ER-positive and HER2-positive
cancers. If subgroups of TNBC with high MT1 activity can
be identified, the possibility exists that melatonin can be
added to the usual chemotherapy. The goal of this study is
to identify the presence or absence of the MT1 melatonin
receptor in TNBC in African American (AA) and Cauca-
sian (C) women, and to explore clinical correlations
between clinicopathologic parameters, cancer markers and
the course of the disease with the expression of MT1.
Methods
With Investigation Review Board (IRB) approval, the
surgical pathology files for 2003 to 2008 at Emory Uni-
versity and Grady Memorial Hospitals (Atlanta, Georgia)
were searched for breast carcinomas that did not immu-
nostain for ER, and PR and which were scored as 0, 1?, or
2? immunohistochemically (IHC), with fluorescent in situ
hybridization (FISH) as non-amplified HER2. A total of
167 TNBC were identified in which formalin fixed paraffin
embedded (FFPE) tissue for MT1 receptor studies was
available. Of these, 84 were AA and 53 C women. Since
not all variables were available in all women, the numbers
in some tables are different. The population statistics of the
AA and C women are summarized in Table 1. An addi-
tional group of five subjects were of Asian descendent.
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Immunohistochemistry
Tissue microarrays (TMA) were constructed using two 1.0-
mm tissue cores from each cancer; 1.0-mm cores of normal
breast tissue were included as controls. TMAs were
immunostained for the MT1 receptor and a series of bio-
markers of interest using the antibodies, positive controls,
and cut-offs for ‘‘positive’’ listed in Table 2. Negative
controls were concurrently run, with the primary antibody
replaced with buffer.
Five micron sections of the TMAs were stained with
predetermined appropriate dilutions using the Dako Auto-
stainer (Dako, Carpinteria, CA). MT1 receptor was deter-
mined with the melatonin receptor antibody in the kit by
Bioscience Research Reagents (formerly Chemicon,
Temecula, CA). In addition to the MT1 receptor, 18
biomarkers were evaluated in each tissue (Table 2). Anti-
gen retrieval was performed in citrate buffer at pH 6.0
under a pressure of 15 pounds per square inch for 3 min.
For CK8, citrate buffer was replaced by EDTA at pH 8.0.
The EnVision ? Dual Link Kit (Dako) which uses a
polymer was the detection method used according to the
manufacturer’s instructions, with diaminobenzidine as the
chromogen and hematoxylin as counterstain. For androgen
receptor (AR), the LSAB2 DAKO detection kit was used.
All slides were examined by the same experienced breast
pathologist who was blinded in regards to ethnic background
and controls. The immunohistochemical expression of MT1
was semi-quantitatively graded as staining intensity (0, 1, 2,
and 3) and as percentage of cells stained (0–100 %). The
product of these two measurements resulted in a WI. In MT1
receptor staining, a WI of 60 or more was called positive, and
Table 1 Triple negative
carcinomas of the breast
(TNBC) in African American
(AA) and Caucasian
(C) women: number, ethnicity,
and age of patients with TNBC
Ethnic group Below 50 years Above 50 years All Patients
No. Age No. Age No. Age
Mean ±SD Mean ±SD Mean ±SD
African American 35 38.7 6.6 46 61.2 8.9 81 51.4 13.7
Caucasian 10 43.9 4.8 43 62.7 10.4 53 59.1 12.1
Table 2 Antibodies used for immunohistological analysis
Antibody Clone Dilution Source Positive control Cut-off
valuesa
Melatonin receptor MT1 OPA1-15641 1:40 Bioscience Research Pineal WIb [ 60
CK5 or 5/6 D5/16B4 1:80 DAKO Mesothelioma 5 %
CK7 OB-TL 12/30 1:40 DAKO Non-small cell carcinoma of the lung 5 %
CK8 35BH11 1:40 DAKO Pancreatic carcinoma 5 %
CK14 NCL-LL002 1:40 Novocastra Placenta 5 %
CK18 DC10 1:10 DAKO Carcinoid tumor 5 %
CK19 BA17 1:50 DAKO Colon carcinoma 5 %
Vimentin V9 1:320 DAKO Signet ring cell carcinoma 5 %
CD44 DF-1485 1:2 Zymed Prostate 5 %
c-Kit (CD 117) Polyclonal 1:800 DAKO Gastrointestinal stromal tumor 1 %
Epidermal growth factor
receptor (EGFR)
FDA-Approved kit Pre diluted DAKO Colon carcinoma 1 %
Insulin-like growth factor
receptor (IGFR)
Polyclonal 1:80 Santa Cruz Biotech Prostate cancer WTb [ 200
P-cadherin (P-CADH) 56C1 1:40 Novocastra Placenta 10 %
p53 D07 1:80 DAKO Colon carcinoma 10 %
p63 4A4 1:160 Neomarkers Squamous cell carcinoma o f skin 1 %
Topoisomerase (TOPO) Ki-Sl 1:160 DAKO Melanoma of the skin 5 %
Androgen receptor (AR) F39.4.1 1:40 DAKO Breast carcinoma 5 %
Ki-67 Mib-1 1:160 DAKO Tonsil 10 %
Survivin (SVNC) 3F343 (SC-73083) 1:60 Santa Cruz Biotech Lymph node 10 %
ZEB E20 (SC-10572) 1:100 Santa Cruz Biotech Breast cancer 10 %
a Percentage of cells with antibody staining
b Weighted index (WI): Intensity of staining 9 Percentage of positive cells
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any WI below this cut-off was negative (Fig. 1). The con-
cordance of two separate cores for MT1 was assessed in 91
patients, and for each core the expression of MT1 was cat-
egorized as positive and negative. Kappa statistics were used
with j = 0.54 (p \ 0.001).
Suitable cut-off values, based upon percentage of cells
staining, and WIs were determined individually for each of
the other markers as listed in Table 2. Carcinomas were
considered positive if the percentage of cells with antibody
staining was greater than or equal to the cut-off value of the
respective marker. Percentages (0–100 %) were averaged
between the two cores. Antigen expression is cytoplasmic
for MT1, cytokeratins, vimentin, and CD44; membranous
for c-Kit, EGFR, and P-cadherin; and nuclear for p53, p63,
topoisomerase (TOPT), AR, Ki-67, and survivin.
Statistical methods
The optimal cut point for MT1 was determined by the
maximum log rank test statistic method [47] based on MT1
WI. For univariate association with MT1 (negative vs.
positive), numerical covariates were analyzed by ANOVA/
Wilcox sum rank test and Chi-Square/Fisher’ exact test for
categorical covariates. Multivariable logistic regression
model was conducted to predict MT1 negative by back-
ward elimination, in which a start up variable list contains
all significant variables in the univariate association.
Progression free survival (PFS) and overall survival
(OS) were associated with each clinical characteristic and
immunohistochemical (IHC) MT1 expression individually
and followed by a multivariable analysis through the Cox
proportional hazards model by backward elimination, in
which a start up variable list contains all significant vari-
ables in the univariate survival analysis. The OS is defined
as days from date of diagnosis to either date of death, if the
patient died, or to date of the last follow-up, if the patient is
still alive. The PFS is defined as days from the date of
diagnosis to the date of the first local recurrence or the first
metastasis, whichever is earlier, if the patient progresses, or
to the date of the last follow-up if the patient does not
progress.
The correlation between two biomarkers was performed
using the Spearman correlation coefficient.
The analyses and summary tables were done using SAS
9.2. The significance level was set at 0.05.
Results
MT1 receptor and clinical characterizations
Table 3 shows the univariate correlation of MT1 with
clinical characteristics at time of diagnosis. In regards to
age, younger women with TNBC more frequently lacked
MT1 expression. The difference was striking between
ethnicities. AA women were more frequently MT1 nega-
tive (48.8 % in AA vs. 11.8 % in C). We conducted a
multivariable logistic regression analysis for predicting
negative MT1 expression, the odds ratio (OR) for AA
compared to C was 5.91 (p = 0.001) after taking tumor
size into account, which indicates that the relationship of
MT1 expression with race was independent of the size of
the tumors. The WI in patients below and above 50 years
of age, was significantly higher in the C as compared to AA
women (Table 4). A family history of breast cancer was
more frequently associated with negative MT1 expression.
MT1-positive TNBCs were associated with a lower
stage and with smaller mean tumor size at time of diag-
nosis. Neoadjuvant chemotherapy prior to surgery, grade of
NegativePositive
Fig. 1 TNBC immunostained with polyclonal MT1E for MT1 melatonin receptor (409). Left MT1 positive, right MT1 negative
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the tumor, lymphovascular invasion, and lymph node and
distant metastases at the time of diagnosis in univariate
analysis did not correlate with the MT1 expression.
MT1 receptor expression and PFS and OS
In multivariable survival analysis of TNBC in AA and C
patients combined, tumors negative for MT1 showed sig-
nificantly shorter PFS (hazard ratio, HR = 1.909,
p = 0.0343) and OS (HR = 2.015, p = 0.0257), as did
NPI, the Nottingham Prognositic Index [48], (PFS
HR = 1.434, p = 0.0344; OS HR = 1.444, p = 0.0259)
(Table 5). Stage I/II tumors showed a better PFS and OS
compared to stage III/IV tumors (Table 5). Table 5 shows
that MT1 is independent to NPI and Stage in terms of
predicting survival. In other words, it indicates that after
taking patient’s disease characteristics (tumor size, LN,
stage, grade as expressed by the Nottingham Prognostic
Index) into account, MT1 makes an additional significant
contribution to predict patient’s survival. In considering the
ethnic groups separately, the differences in survival
advantage of MT1 positivity and increase in HR with
absence of MT1 expression was statistically significant in
the entire group of patients with AA and C combined. It
was especially pronounced in the AA women, but did not
reach statistical significance in the smaller number of C
women alone (Table 6). In regards to age, MT1 positivity
was statistically significantly related to improved PFS or
OS in the women above 50 years of age but not in the
smaller group of women below 50 years of age (Table 7).
Figure 2 shows the Kaplan–Meier survival curves for PFS
and OS in AA and C women combined with MT1 positive
and MT1 negative TNBC. Figure 3 shows the comparable
behavior in both subpopulations.
Correlation of MT1 WI and other biomarkers in TNBC
in AA and C women
The absolute values of the biomarkers studied and their
interracial differences were discussed in a series of publi-
cations from this laboratory [39, 49–51], and only their
correlations with the MT1 receptor will be presented here.
The correlation between MT1 expression, WI, and the
other biomarkers studied is shown in Table 8 separately
and together for AA and C women and in Table 9
according to age.
The TNBC in the C women (N = 10–51 women avail-
able for different biomarkers) showed a negative Spearman
Table 3 Univariate correlation
of MT1 melatonin receptor in
triple negative breast cancers




a The parametrical p value is
calculated by ANOVA for
numerical covariates and Chi-
square test for categorical
covariates
b The non-parametrical p value
is calculated by Wilcoxon
statistics for numerical and
Fisher’s exact test for
categorical covariates
Covariate Level Number Parametric p valuea Non-parametric
p valueb
Positive Negative
Age \40 9 12 0.046 0.053
40–60 50 24
[60 33 12
Race Caucasian 45 6 <0.001 <0.001
African American 43 41
Family history of
breast cancer
No 39 14 0.030 0.044
Yes 19 18
Stage I/II 68 26 0.017 0.029
III/IV 21 20
Tumor size Number 92 48 0.002 0.027
Mean 2.42 3.92
Median 2.15 2.50
Table 4 ANOVA summary MT1 receptor expression: ethnicity and age
F test p Value Ethnic group Age (years) Number Mean SE p \ 0.05
11.851 0.0001 African American \50 35 69.06 12.26 \50: AA vs. Ca
Caucasian [50 46 74.82 12.05 [50: AA vs. Cb
\50 10 138.50 28.15
[50 43 170.60 16.27
MT1 receptor expression as weighted index (staining intensity 9 percentage of stained cancer cells). Ranges from 0 to 300
a By Fisher PLSD
b By Fisher PLSD and Scheffe F test
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correlation coefficient between the WI of melatonin and the
expression of CK14 (-0.307, p = 0.032) and p53 (-0.422,
p = 0.003) with no statistically significant correlation to
any other biomarker (Table 8).
In the AA women (N = 64–84 women available for
different biomarkers), there was a positive correlation of the
WI of MT1 with CD44 (0.258, p = 0.020), CK7 (0.262,
p = 0.017), and CK8 (0.284, p = 0.011) and a negative
correlation with EGFR (-0.219, p = 0.049), Ki-67
(-0.332, p = 0.002), and survivin (-0.324, p = 0.003).
When the biomarkers in the entire group of TNBC of
both AA and C were examined together irrespective of age,
Table 5 Multivariate correlation of MT1 melatonin receptor in triple negative breast cancers with progress free survival (PFS) overall survival
(OS) and with clinical characteristics at time of diagnosis
Variable No. of subjectsa Level Progress free survival (PFS) Overall survival (OS)
Hazard ratio Pr [ Chi Sq Hazard ratio Pr [ Chi Sq
MT1 receptor 44 Negative 1.909 0.0343 2.015 0.0257
89 Positive (ref)
NPIb 133 1 Unit increase 1.434 0.0344 1.444 0.0259
Stage 94 I/II 0.059 <0.0001 0.138 <0.0001
39 III/IV (ref)
Statistically significant values are in bold
a The total number used in the multivariable analysis was 133 patients
b NPI (Nottingham Prognostic Index): 0.2 9 tumor size (cm) ? LN (0 = 1, 1–3 = 2, [3 = 3) ? Grade
Table 6 Tumor progression free survival (PFS) and overall survival (OS) in African American and Caucasian American women with triple
negative breast cancer (TNBC) negative or positive (score C 60) for MT1 melatonin receptor: survival analysis by race
Survival TNBC-MT1 receptor negative vs. positive
Statistics African American Caucasian Combined
Progression free survival Hazard ratio 2.27 1.97 2.22
p Value 0.022 0.311 0.006
N 84 51 137
Overall survival Hazard ratio 2.46 2.01 2.46p V lue 0 012 0 386 0 003
N 84 51 137
Statistically significant values are in bold
Table 7 Tumor progression free survival (PFS) and overall survival
(OS) in patients above and below 50 years of age with triple negative
breast cancer (TNBC) negative or positive (score C 60) for MT1
melatonin receptor: survival analysis by age
Survival TNBC-MT1 receptor negative vs. positive
Statistics Age \ 50 Age [ 50 Combined
Progression free
survival (PFS)
HRa 1.62 2.66 2.12
p Value 0.269 0.011 0.009
N 54 86 140
Overall survival
(OS)
HRa 2.02 2.95 2.42
p Value 0.124 0.008 0.003
N 54 86 140
Statistically significant values are in bold
a Hazard ratio



























































Fig. 2 Overall and progression free survival of patients with TNBC
with and without MT1 melatonin receptors
682 Breast Cancer Res Treat (2013) 137:677–687
123
positive correlations of the WI of MT1 was found with the
AR (0.191, p = 0.026), CD44 (0.303, p \ 0.001), CK19
(0.310, p \ 0.001), CK5 (0.330, p \ 0.001), CK7 (0.279,
p = 0.001), CK8 (0.367, p = 0.001), and IGFR (0.257,
p = 0.006), and negative correlations were observed with
Ki-67 (-0.326, p \ 0.001), p53 (-0.296, p \ 0.001), and
survivin (-0.256, p = 0.011). For survivin, only 10 tumors
were available in C. The WI of CK5/6, c-Kit, p63,
p-CADH, TOPO, UPARNC, Vimentin, and ZEB did not
show any statistically significant correlation with MT1
receptors in AA or C-tumors.
The analysis based on this database could not confirm that
the status of Ki-67 and p53 can predict OS or PFS, and hence
was not able to assess the independence of MT1 relative to
those two biomarkers in terms of survival. However, based
on the multivariate analysis (Table 5), we can conclude that
MT1 was independent of stage and NPI (Nottingham Prog-
nostic Index: 0.29 tumor size (cm) ? LN ? Grade).
Compared according to age AA and C patients combined
(Table 9) showed in the TNBC of women below 50 years of
age, a positive correlation between the WI of MT1 and the
expression of CD44, CK19, CK8, and IGFR, and a negative
correlation with p53 and survivin. In women above 50 years
of age, there were statistically significant positive correla-
tions between MT1 and AR, CD44, CK19, CK5, CK7, and
C8, and negative correlations with Ki-67 and p53. In both
age groups combined, a positive correlation was found in
AR, CD44, CK18, CK19, CK5, CK7, CK8, IGFR, and a
negative correlation in Ki-67, p53, and survivin.
Discussion
MT1 receptors were present in a percentage of TNBC with
marked differences in expression between AA and C
women. The frequency and staining intensity of MT1
expression was significantly higher in the tumors in C as
compared to AA women. This difference between the
TNBC in C and in AA women is of interest in view of their
different biologic behaviors [37, 39, 52]. In regards to the
course of the disease, patients with absent or low MT1
expression showed a worse prognosis with shorter DFS and
OS‘ than patients with MT1-positive tumors. This was
manifest in the population as a whole with AA and C
combined, and was statistically significant in the AA
TNBC, but did not quite reach statistical significance in the
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Fig. 3 Overall and progression free survival of African American
and Caucasian Women with TNBC with and without MT1 melatonin
receptors
Table 8 Correlation between
MT1 expression (as weighted






Biomarker African American (AA) Caucasian (C) AA ? C Combined
Coefficienta p Value N Coefficienta p Value N Coefficienta p Value
Androgen receptor
(AR)
0.098 0.380 82 0.203 0.158 50 0.191 0.026
CD44 0.258 0.020 81 0.172 0.228 51 0.303 <0.001
CK14 0.030 0.792 82 -0.307 0.032 49 -0.058 0.503
CK18 0.025 0.825 81 -0.907 0.506 49 0.194 0.024
CK19 0.171 0.122 83 0.059 0.687 49 0.310 <0.001
CK5 -0.172 0.119 84 0.102 0.481 50 0.330 <0.001
CK7 0.262 0.017 82 0.003 0.982 50 0.279 0.001
CK8 0.284 0.011 80 0.111 0.441 50 0.367 <0.001
EGFR -0.219 0.049 82 -0.065 0.656 50 -0.069 0.425
IGFR 0.000 0.997 64 0.137 0.374 44 0.257 0.006
Ki67 -0.332 0.002 83 -0.150 0.298 50 -0.326 <0.001
p53 -0.197 0.076 82 -0.422 0.003 49 -0.296 <0.001
SVNC -0.324 0.003 82 0.472 0.168 10 -0.256 0.011
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a higher positivity rate and stronger expression of MT1 and
a more favorable prognosis than the AA group. MT1
expression was associated with other prognostically
favorable features like smaller tumor size and lower grade
at the time of diagnosis, which appears to be associated
with less aggressive TNBC with more favorable outcome.
MT1 was negatively correlated with the proliferation
marker Ki-67 which is associated with an unfavorable
outcome in other forms of breast cancer [53, 54], and in the
AA only with EGFR, which is also associated with an
unfavorable outcome in TNBC [38, 55]. In this context, the
possibility of a loss of MT1 expression through clonal
evolution in the larger and more aggressive tumors may
have to be considered. MT1 expression was uniform at
different sites of the same tumor as expressed by the high
degree of concordance.
There appears to be a difference in pineal function and
circulating melatonin concentrations and the development
of breast cancer. Melatonin levels in first morning urine
were reported to show an inverse correlation with breast
cancer risk [56]. Conditions which favor melatonin sup-
pression by light during the night, including shiftwork,
have been reported to represent risk factors for the devel-
opment of breast cancer [56–60]. In human subjects, with
suppression of melatonin, e.g., by light during the night as
experienced by shiftworkers exposed over a prolonged time
span to nightwork, an increase of breast cancer incidence
has been reported [60]. A most recent report found this
increase to occur predominantly in TNBC [61].
A strong inverse correlation was observed between cir-
culating plasma melatonin concentration and the amounts
of ER and PR in the primary tumor [62]. There is a relation
between the circadian rhythms in plasma melatonin and
the steroid receptor content of the primary breast cancer.
Women with ER or PR positive tumors show a signifi-
cantly lower mean plasma melatonin day–night difference
than did patients with ER or PR negative tumors [62].
Melatonin acts over several signaling pathways that
control normal breast epithelium and breast cancer [6, 63–
66]. The anti-proliferative effects of the circadian melato-
nin signal are in general, but not exclusively, mediated by
activation of MT1.
In ER-positive human breast cancer cells, melatonin
suppresses ERa mRNA expression and estrogen-induced
transcriptional activity [23]. Melatonin regulates the tran-
scriptional activity of other members of the nuclear
receptor super family of enzymes involved in peripheral
estrogen metabolism. Beyond that melatonin blocks the
uptake of linoleic acid and its transformation in 13-hy-
droxyoctadecadienoic acid (HODE), a mitogenic com-
pound [64]. Melatonin also exerts anti-invasive and anti-
metastatic effects through blockade of 38 phosphorylation
and matrix metalloprotein expression [6, 63].
Overexpression of the MT1 receptor in transfected
MCF-7 human breast cancer cells induced inhibition of
aromatase mRNA expression [24] and inhibited human
MCF-7 cell proliferation-derived mammary tumor forma-
tion in male mice [67, 68]. Melatonin agonists exhibit
enhanced antitumor potency in experimental models [23].
Additional new melatonin agonists with a variation of
properties are being developed in research laboratories and
by industry [5, 69, 70]. The anti-proliferative effect of MT1
receptor overexpression was blocked by a MT1/MT2
receptor antagonist (S20928 Servier) [67].
Manipulation of MT1 receptors by the anti-epileptic
valproic acid has been reported and may be of interest
for enhancement of melatonin effects upon cell prolifera-
tion. Clinically relevant concentrations of valproic acid
Table 9 Correlation between
MT1 expression (as weighted






Biomarker \50 years of age [50 years of age All ages
Coefficienta p Value N Coefficienta p Value N Coefficienta p Value
Androgen
receptor (AR)
0.010 0.943 51 0.273 0.012 85 0.191 0.026
CD44 0.355 0.010 52 0.269 0.013 85 0.303 <0.001
CK14 -0.110 0.432 53 -0.005 0.966 83 -0.058 0.503
CK18 0.181 0.200 52 0.150 0.180 82 0.194 0.024
CK19 0.355 0.010 52 0.259 0.018 84 0.310 <0.001
CK5 0.133 0.338 54 0.436 <0.001 84 0.330 <0.001
CK7 0.217 0.119 53 0.280 0.010 84 0.279 0.001
CK8 0.296 0.032 53 0.375 0.001 81 0.367 <0.001
EGFR -0.104 0.461 52 -0.033 0.768 84 -0.069 0.425
IGFR 0.313 0.041 43 0.216 0.075 69 0.257 0.006
Ki67 -0.233 0.091 54 -0.383 <0.001 84 -0.326 <0.001
p53 -0.306 0.026 53 -0.280 0.011 82 -0.296 <0.001
SVNC -0.358 0.020 42 -0.214 0.116 55 -0.256 0.011
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upregulate melatonin MT1 receptor expression in human
breast cancer cells (MCF-7B) [71]. There was an enhanced
anti-proliferation effect on these cells through a combina-
tion of valproic acid and melatonin [71]. Tumor cell
growth inhibition in vitro and in vivo by valproic acid and
other anti-epileptic agents has been reported in animal
experiments [72–76]. The anti-proliferation effect of anti-
epileptic drugs may be related to their MT1 up-regulation.
Although the association of the MT1 expression with a
more favorable course of TNBC is not direct evidence for
melatonin effects on this tumor, the extensive experimen-
tation on the mechanistic aspects of apparent melatonin
effects makes a causal relation appear likely.
Randomized controlled trials of melatonin treatment,
including breast cancer, have been evaluated in two meta-
analyses of published reports [77, 78]. It was concluded that
melatonin as an adjuvant therapy to cancer may lead to
improvement in tumor remission and survival and may
ameliorate the side-effects of chemotherapy or radiother-
apy. Our findings of the apparently favorable aspects of
MT1 receptor expression in patients with TNBC support
these findings and suggest the possible utility of melatonin
or of longer acting melatonin agonists [23] in TNBC, a type
of tumor for which no other targeted treatment is available
at this time. This effect may be linked to the presence of
MT1 receptors in the tumor but also other mechanisms like
immune stimulation by melatonin [79] have to be consid-
ered. More research in this direction is needed.
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